1. Trg lesa v času COVID-19Špela Ščap, Darja Stare, Nike Krajnc, 2020, strokovni članek Ključne besede: Slovenija, gozdarstvo, okrogli les, les za kurjavo, žagarstvo, trg, epidemije, Covid-19
Objavljeno v DiRROS: 16.09.2022; Ogledov: 76; Prenosov: 13
 Celotno besedilo (3,08 MB) |
2. Stanje na trgu okroglega lesa in lesnih proizvodov v Sloveniji v letih 2019 in 2020Špela Ščap, Nike Krajnc, Darja Stare, Tomaž Remic, 2020, strokovni članek Ključne besede: Slovenija, okrogli les, trg, lesni proizvodi, gozdarstvo, epidemije, Covid-19, poraba
Objavljeno v DiRROS: 16.09.2022; Ogledov: 76; Prenosov: 21
Celotno besedilo (2,26 MB) |
3. |
4. Lastnikom gozdov svetujemo : ne sekajte, če ni nujnoNike Krajnc, Špela Ščap, 2020, strokovni članek Ključne besede: sečnja, gozdovi, les, gozdno lesni sortimenti, gozdarstvo, Covid 19, epidemija, trgovanje
Objavljeno v DiRROS: 16.09.2022; Ogledov: 60; Prenosov: 22
Celotno besedilo (1,97 MB) |
5. Težave v mednarodnem pretoku lesa in lesnih izdelkov v srednji Evropi ter stanje na trgu lesnih proizvodov v Sloveniji v času epidemije Koronavirus COVID–19Špela Ščap, 2020, strokovni članek Ključne besede: mednarodni trg, trg lesa, trg lesnih proizvodov, Srednja Evropa, Slovenija, gozdarstvo, lesarstvo, gozdovi, epidemije, Covid-19, prevoz lesa
Objavljeno v DiRROS: 16.09.2022; Ogledov: 96; Prenosov: 22
Celotno besedilo (2,77 MB) |
6. |
7. Effect of hydroxychloroquine in hospitalized patients with Covid-19Peter Horby, Marion Mafham, Martin J. Landray, 2020, izvirni znanstveni članek Povzetek: Background: Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrolled studies and small, randomized trials. Methods: In this randomized, controlled, open-label platform trial comparing a range of possible treatments with usual care in patients hospitalized with Covid-19, we randomly assigned 1561 patients to receive hydroxychloroquine and 3155 to receive usual care. The primary outcome was 28-day mortality. Results: The enrollment of patients in the hydroxychloroquine group was closed on June 5, 2020, after an interim analysis determined that there was a lack of efficacy. Death within 28 days occurred in 421 patients (27.0%) in the hydroxychloroquine group and in 790 (25.0%) in the usual-care group (rate ratio, 1.09; 95% confidence interval [CI], 0.97 to 1.23; P = 0.15). Consistent results were seen in all prespecified subgroups of patients. The results suggest that patients in the hydroxychloroquine group were less likely to be discharged from the hospital alive within 28 days than those in the usual-care group (59.6% vs. 62.9%; rate ratio, 0.90; 95% CI, 0.83 to 0.98). Among the patients who were not undergoing mechanical ventilation at baseline, those in the hydroxychloroquine group had a higher frequency of invasive mechanical ventilation or death (30.7% vs. 26.9%; risk ratio, 1.14; 95% CI, 1.03 to 1.27). There was a small numerical excess of cardiac deaths (0.4 percentage points) but no difference in the incidence of new major cardiac arrhythmia among the patients who received hydroxychloroquine. Conclusions: Among patients hospitalized with Covid-19, those who received hydroxychloroquine did not have a lower incidence of death at 28 days than those who received usual care. (Funded by UK Research and Innovation and National Institute for Health Research and others; RECOVERY ISRCTN number, ISRCTN50189673; ClinicalTrials.gov number, NCT04381936.).
Ključne besede: Covid-19 -- drug therapy, hydroxychloroquine, chloroquine
Objavljeno v DiRROS: 30.05.2022; Ogledov: 148; Prenosov: 88
 Povezava na datoteko
Gradivo ima več datotek! Več... |
8. Dexamethasone in hospitalized patients with Covid-19Peter Horby, Wei Shen Lim, Martin J. Landray, 2021, izvirni znanstveni članek Povzetek: Background: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death. Methods: In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone. The primary outcome was 28-day mortality. Here, we report the final results of this assessment. Results: A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P<0.001). The proportional and absolute between-group differences in mortality varied considerably according to the level of respiratory support that the patients were receiving at the time of randomization. In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.92 to 1.55). Conclusions: In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. (Funded by the Medical Research Council and National Institute for Health Research and others; RECOVERY ClinicalTrials.gov number, NCT04381936; ISRCTN number, 50189673.).
Ključne besede: Covid-19 -- drug therapy, dexamethasone
Objavljeno v DiRROS: 30.05.2022; Ogledov: 150; Prenosov: 119
Povezava na datoteko
Gradivo ima več datotek! Več... |
9. |
10. Allergies and COVID-19 vaccines : an ENDA/EAACI position paperAnnick Barbaud, Lene Heise Garvey, Alessandra Arcolaci, Knut Brockow, Francesca Mori, Cristobalina Mayorga, Maja Jošt, Mitja Košnik, Mihaela Zidarn, Maria J Torres, 2022, izvirni znanstveni članek Povzetek: Anaphylaxis, which is rare, has been reported after COVID 19 vaccination, but its management is not standardized. Method. Members of the European Network for Drug Allergy and the European Academy of Allergy and Clinical Immunology interested in drug allergy participated in an online questionnaire on pre-vaccination screening and management of allergic reactions to COVID-19 vaccines, and literature was analysed. Results. No death due to anaphylaxis to COVID-19 vaccines has been confirmed in scientific literature. Potential allergens, polyethylene glycol (PEG), polysorbate and tromethamine, are excipients. The authors propose allergy evaluation of persons with the following histories: 1- anaphylaxis to injectable drug or vaccine containing PEG or derivatives; 2- anaphylaxis to oral/topical PEG containing products; 3-recurrent anaphylaxis of unknown cause; 4-suspected or confirmed allergy to any mRNA vaccine, 5-confirmed allergy to PEG or derivatives. We recommend a prick-to-prick skin test with the left over solution in the suspected vaccine vial to avoid waste. Prick test panel should include PEG 4000 or 3500, PEG 2000 and polysorbate 80. The value of in vitro test is arguable. Conclusions. These recommendations will lead to a better knowledge of the management and mechanisms involved in anaphylaxis to COVID-19 vaccines and enable more people with history of allergy to be vaccinated.
Ključne besede: SARS-CoV-2, COVID-19, COVID-19 vaccines, allergens, anapylaxis, drug hypersensitivity
Objavljeno v DiRROS: 07.02.2022; Ogledov: 279; Prenosov: 89
Povezava na datoteko |
